, Volume 10, Issue 4, pp 257-260
Date: 08 Jun 2010

Use of Medications to Lower Urine Protein Level in Patients With Diabetic Kidney Disease

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

Trial

Mehdi UF, Adams-Huet B, Raskin P, et al.: Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 2009, 20:2641–2650.

Rating

Of interest.

Clinical Trial Acronyms

  1. Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation

  2. Candesartan in Heart Failure Assessment of Reduction in Morbidity and Mortality

  3. Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial

  4. Valsartan Heart Failure Trial

Introduction

Aldosterone promotes glomerular and tubular sclerosis independent of angiotensin II in animal models of diabetic nephropathy. Most human studies testing the renoprotective benefit of adding an angiotensin receptor blocker (ARB) or a mineralocorticoid receptor antagonist to a regimen based on inhibition of angiotensin-converting enzyme (ACE) used relatively low doses of ACE inhibitors (ACEIs). ...